Inhibitors of KRAS G12C mutant proteins
US10647703B2 · kind B2 · utility
18Cited by
59References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 27, 2016 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Sep 27, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, X, R3a, R3b, R4a, R4b, G1, G2, G3, G4, L1, L2, m1, m2, m3, m4, and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.